• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Gero Raises $6M for Physics-Powered GenAI Biotech

by Syed Hamza Sohail 10/20/2023 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

  • Gero, a biotechnology company focused on aging and chronic diseases, has closed $6M in a Series A extension round.
  • This funding round positions Gero to continue internal drug development programs, grow its scientific team to boost platform technology development, and expand its US presence. The round was led by Melnichek Investments, a Cyprus-based VC firm that seeks to improve the quality of human lives by funding and supporting promising, potentially high-impact, machine-learning startups, with the participation of VitaDAO and Leonid Lozner.

Exploring New Horizons with Cutting-Edge Generative AI Tools


By applying cutting-edge generative AI tools to analyze real-world longitudinal human health data, Gero is dedicated to finding novel cures for age-related diseases. Its goal is to unravel the mysteries behind human aging and halt the aging process.

“The large health model that we have trained is instrumental in the discovery of therapies targeting aging and age-related diseases, both in-house and via collaborations with pharmaceutical companies,” said Peter Fedichev, Gero co-founder and CEO. “Thanks to this recent funding from Melnichek Investments, coupled with their expertise in modern AI through backing many successful companies, we are now well positioned to accelerate our progress.”

Earlier this year, Gero announced a research partnership with Pfizer and is in talks with other pharmaceutical companies interested in addressing age-related diseases as a growing market. Gero’s advanced health model distinguishes the effects of aging from those of diseases, potentially transforming genetics-driven drug discovery for common conditions. Melnichek Investments recognized the potential in Gero’s mission to gain insights into the causes of age-related diseases and create new treatments using AI technology. Age-related diseases are complex and require an understanding of vast data sets beyond human capacity. Gero’s work emphasizes the importance of this realization and the solutions it offers. Gero is a leader in the emerging field of medical research, suggesting that aging can be treated and controlled with modern technology, rather than being an unavoidable part of human existence.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Generative AI

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |